198 related articles for article (PubMed ID: 35202953)
1. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).
Moreau-Bachelard C; Campion L; Toulmonde M; Le Cesne A; Brahmi M; Italiano A; Mir O; Piperno-Neumann S; Laurence V; Firmin N; Penel N; Duffaud F; Chevreau C; Bertucci F; Narciso B; Dubray-Longeras P; Delcambre C; Saada-Bouzid E; Boudou-Rouquette P; Soulie P; Perrin C; Blay JY; Bompas E
ESMO Open; 2022 Apr; 7(2):100402. PubMed ID: 35202953
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen.
Salah S; Yaser S; Salem A; Al Mousa A; Abu Sheikha A; Sultan I
Med Oncol; 2013; 30(3):639. PubMed ID: 23780657
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and treatment of patients with advanced synovial sarcoma: A single-center experience.
Ates O; Aksoy S; Yeter H; Sunar V; Kertmen N; Dizdar O; Turker A; Kars A
Indian J Cancer; 2017; 54(1):321-325. PubMed ID: 29199714
[TBL] [Abstract][Full Text] [Related]
4. Systemic Treatment for Adults with Synovial Sarcoma.
Desar IME; Fleuren EDG; van der Graaf WTA
Curr Treat Options Oncol; 2018 Mar; 19(2):13. PubMed ID: 29516254
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States.
Pollack SM; Somaiah N; Araujo DM; Druta M; Van Tine BA; Burgess MA; Chawla SP; Seetharam M; Okuno SH; Bohac C; Chen M; Yurasov S; Attia S
Cancer Med; 2020 Jul; 9(13):4593-4602. PubMed ID: 32374488
[TBL] [Abstract][Full Text] [Related]
6. Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma.
Kojima Y; Shimoi T; Seo T; Yazaki S; Okuya T; Ohtake Y; Okuma HS; Shimomura A; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Tamura K; Yoshida A; Iwata S; Kobayashi E; Kawai A; Fujiwara Y; Yonemori K
Oncology; 2022; 100(7):370-375. PubMed ID: 35405680
[TBL] [Abstract][Full Text] [Related]
7. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
[TBL] [Abstract][Full Text] [Related]
8. Primary Metastatic Synovial Sarcoma: Experience of the CWS Study Group.
Scheer M; Dantonello T; Hallmen E; Vokuhl C; Leuschner I; Sparber-Sauer M; Kazanowska B; Niggli F; Ladenstein R; Bielack SS; Klingebiel T; Koscielniak E
Pediatr Blood Cancer; 2016 Jul; 63(7):1198-206. PubMed ID: 27003095
[TBL] [Abstract][Full Text] [Related]
9. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.
Italiano A; Penel N; Robin YM; Bui B; Le Cesne A; Piperno-Neumann S; Tubiana-Hulin M; Bompas E; Chevreau C; Isambert N; Leyvraz S; du Chatelard PP; Thyss A; Coindre JM; Blay JY
Ann Oncol; 2009 Mar; 20(3):425-30. PubMed ID: 19088169
[TBL] [Abstract][Full Text] [Related]
10. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide.
Rosen G; Forscher C; Lowenbraun S; Eilber F; Eckardt J; Holmes C; Fu YS
Cancer; 1994 May; 73(10):2506-11. PubMed ID: 8174046
[TBL] [Abstract][Full Text] [Related]
11. The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
Goy BW; Syed S; Padmanabhan A; Burchette RJ; Helmstedter CS
Radiother Oncol; 2021 Dec; 165():174-178. PubMed ID: 34758339
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of prognostic factors for synovial sarcoma].
Du ZY; Guo W; Yang RL; Yan TQ; Li DS
Zhonghua Wai Ke Za Zhi; 2011 Nov; 49(11):991-4. PubMed ID: 22333419
[TBL] [Abstract][Full Text] [Related]
13. Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes.
Bajpai J; Khanna N; Vora T; Gulia A; Laskar S; Puri A; Sanduptla B; Chinnaswamy G; Nayak P; Juvekar SL; Janu A; Desai S; Ghosh J; Purandare N; Ramadwar M; Rangarajan V; Rekhi B
Indian J Cancer; 2018; 55(1):37-44. PubMed ID: 30147091
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma.
Eilber FC; Brennan MF; Eilber FR; Eckardt JJ; Grobmyer SR; Riedel E; Forscher C; Maki RG; Singer S
Ann Surg; 2007 Jul; 246(1):105-13. PubMed ID: 17592298
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital.
Spurrell EL; Fisher C; Thomas JM; Judson IR
Ann Oncol; 2005 Mar; 16(3):437-44. PubMed ID: 15653701
[TBL] [Abstract][Full Text] [Related]
16. Response to chemotherapy is not related to chromosome instability in synovial sarcoma.
Chakiba C; Lagarde P; Pissaloux D; Neuville A; Brulard C; Pérot G; Coindre JM; Terrier P; Ranchere-Vince D; Ferrari A; Collini P; Suurmeijer AJH; Blay JY; Terrisse SA; Piperno-Neumann S; Averous G; Bui B; Orbach D; Italiano A; Chibon F
Ann Oncol; 2014 Nov; 25(11):2267-2271. PubMed ID: 25070544
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
18. Synovial Sarcoma of the Hand and Foot: An Institutional Review.
Patel RR; Lupo PJ; Bishop AJ; Lin PP; Delclos GL; Lazar AJ; Benjamin RS; Araujo DM
Am J Clin Oncol; 2021 Jul; 44(7):361-368. PubMed ID: 33927134
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
20. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.
Wagner MJ; Gopalakrishnan V; Ravi V; Livingston JA; Conley AP; Araujo D; Somaiah N; Zarzour MA; Ratan R; Wang WL; Patel SR; Lazar A; Ludwig JA; Benjamin RS
Oncologist; 2017 Oct; 22(10):1271-1277. PubMed ID: 28710342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
